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Lesion types and device characteristics that predict
distal embolization during percutaneous lower
extremity interventions
Gautam V. Shrikhande, MD, Sikandar Z. Khan, MD, Hafiz G. Hussain, MD, Rajeev Dayal, MD,
James F. McKinsey, MD, and Nicholas Morrissey, MD, New York, NY
Objective: Distal embolization (DE) during percutaneous lower extremity revascularization (LER) may cause severe
clinical sequelae. To better define DE, we investigated which lesion types and treatment modalities increase the risk for
embolization.
Methods: A prospective registry of LER from 2004 to 2009 was reviewed. All cases with runoff evaluated before and after
intervention were included. Angiograms and operative reports were reviewed for evidence of DE. Interventions included
percutaneous transluminal angioplasty (PTA), with or without stent placement, and atherectomy with four different
devices. Chi-square analysis and Fisher’s exact test were used to assess significance. Patency rates were calculated using
Kaplan-Meier analysis and compared using log-rank analysis.
Results: There were 2137 lesions treated in 1029 patients. The embolization rate was 1.6% (34 events). Jetstream
(Pathway, Kirkland, Wash) and DiamondBack 360 (Cardiovascular Systems Inc, St Paul Minn) devices had a combined
embolization rate of 22% (8 of 36), 4 of 18 (22%) in each group, which was significantly higher than with PTA alone (5
of 570, 0.9%), PTA and stent (5 of 740, 0.7%), SilverHawk (ev3, Plymouth, Minn) atherectomy (14 of 736, 1.9%), and
laser atherectomy (2 of 55, 3.6%; P < .001). There was a significantly higher rate of embolization for in-stent restenosis (6
of 188, 3.2%) and chronic total occlusions (15 of 615, 2.4%) compared with stenotic lesions (13 of 1334, 0.9%; P .01). The
embolization rate was significantly higher in Transatlantic Inter-Society Consensus (TASC) II C andD lesions comparedwith
TASC A and B lesions (P .018). DE rates were not affected by preoperative runoff status (P .152). Patency was restored
at the completion of the procedure in 32 of 34 cases of DE. The 24-month primary patency, assisted primary patency, and
secondary patency in the DE group was 54.0% 11.9%, 70.0% 10.3%, and 73.2% 10.3%, respectively, and was 44.4%
1.7%, 61.5% 1.7%, and 68.2% 1.6%, respectively, when embolization did not occur (P> .05). Limb salvage was 72.6%
3.1% in lesions in which no DE occurred vs 83.3%  15.2% in lesions in which DE occurred (P  .699).
Conclusions: DE is a rare event that occurs more often with the Jetstream and DiamondBack 360 devices. In-stent and
complex native lesions are at higher risk for DE. DE is typically reversible with endovascular techniques and has no effect
on patency rates and limb salvage. (J Vasc Surg 2011;53:347-52.)
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uDistal embolization (DE) during percutaneous arterial
intervention is a major concern due to potential severe isch-
emic consequences. The use of distal protection to prevent
embolization during intervention in coronary saphenous vein
grafts1 and carotid angioplasty and stenting2-4 is well estab-
lished. It is logical that concern would exist for the potential
adverse effect of particulate emboli on lower extremity circu-
lation during aggressive manipulation of plaque and throm-
bus.5 Limb salvage is based on revascularization and mainte-
nance of runoff vessels in the leg and foot, and therefore, the
potential impact of macroembolization is significant. As per-
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doi:10.1016/j.jvs.2010.09.008utaneous lower extremity intervention becomes common-
lace anddevices are rapidly introduced, it is necessary that the
ates of distal embolization be better defined.
The incidence of significant embolization has been
stimated at 1% to 5%.6-8 The rate of particulate emboliza-
ion during various procedures has been examined by de-
ecting debris with a popliteal Doppler probe.6 Although
articulate emboli can occur in all phases of intervention,
he rate of angiographically significant embolization was
%. This resulted in a clinically significant event rate of 1% as
ell. In similar studies emboli were detected by ultrasound
onitoring during iliac intervention.9,10 These studies in-
olved numbers too small to make conclusions on risk
actors for the development of clinically or angiographically
ignificant embolization.
The concern for embolization has led some to recom-
end the use of distal protection devices during interven-
ion on certain lesions. There has been some evidence that
therectomy may be more emboligenic than angioplasty
ith or without stenting and therefore may benefit from
istal protection.11 Although these devices could benefit
ome patients, the proper lesion and patient characteristics
ave not been defined. Published reports have involved the
se of protection devices and confirmation of the presence
f debris without a control group to confirm clinical effi-
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February 2011348 Shrikhande et alcacy.12-15 The rates of embolization with newer atherectomy
devices such as the Jetstream (Pathway Medical Technologies,
Kirkland, Wash) and DiamondBack 360 (Cardiovascular Sys-
tems Inc [CSI],Minneapolis,Minn) atherectomydevices arenot
clearly understood.
The purpose of this study was to determine the rate of
angiographically evident embolization during percutane-
ous lower extremity arterial intervention with several avail-
able treatment modalities and define its clinical impact. In
addition, we hoped to identify lesion types that might be
more prone to embolization and stratify different tech-
niques for their emboligenic potential.
METHODS
Data collection and patient selection. Between the
years 2004 and 2009, all infrainguinal lower extremity
arterial lesions treated percutaneously for chronic lower
extremity ischemia were identified in a prospectively main-
tained database. Indications for intervention included de-
bilitating claudication or critical limb ischemia, defined as
rest pain, tissue loss, or nonhealing ulceration. Patients
with acute limb ischemia were excluded.
Operative reports and angiograms were examined by a
separate reviewer to determine lesion type and Transatlan-
tic Inter-Society Consensus (TASC) II classification.16 All
angiograms were reviewed for preoperative and postopera-
tive treatment vessel and runoff vessel status. Angiographi-
cally significant embolization was defined as a change in any
visualized runoff vessel (other than vasospasm and dissection)
at any time during the procedure. Postoperatively, patients
were monitored by physical examination to assess clinical
outcome, including pulse examination. Patency rates were
obtained by postoperative duplex ultrasound surveillance at 1,
3, 6, and 12 months, and annually thereafter.
Devices and technique. Percutaneous interventions
included percutaneous transluminal angioplasty (PTA),
with or without stent placement, and atherectomy with the
following: the directional SilverHawk (ev3, Minneapolis,
Minn) atherectomy device, the orbital atherectomy
DiamondBack 360 device, the rotational atherectomy Jet-
stream G2 device, and the laser atherectomy Excimer Laser
device (Spectranetics, Colorado Spring, Colo).
Most procedures were performed under local anesthe-
sia with intravenous sedation. Activated clotting time was
maintained 250 seconds. For all interventions, 5F to 8F
sheaths were used. Lesions were crossed with either a
luminal or subintimal technique using hydrophilic guide-
wires (0.035, 0.018, or 0.014 inch). Balloon angioplasty
was performed with appropriately sized noncompliant
balloons, with inflation times ranging from 60 to 180
seconds at 6 to 15 atm of pressure. Atherectomy devices
were used at the discretion of the operating surgeon.
Completion angiography with evaluation of the distal
runoff was performed after all interventions. In case of
embolization, the salvage techniques included using an
Export aspiration catheter (Medtronic Vascular, Santa
Rosa, Calif) and mechanical thrombectomy (AngioJet cltra Thrombectomy System Medrad Interventional/
ossis, Minneapolis, Minn).
Statistical analysis. Clinical significance was assessed
ith 2 analysis and Fisher’s exact test based on P .05 for
ategorical data. Patency rates were calculated using
aplan-Meier analysis and compared using log-rank analysis.
ultivariate Cox regression analysis was done to identify
ndependent predictors of patency and limb salvage. All anal-
sis was done using SPSS 17.0 software (SPSS Inc, Chicago, Ill).
ESULTS
Demographics. There were 2137 lesions treated in
029 patients. Demographic data and risk factors are out-
ined in Table I. The indications for intervention were
able I. Patient demographics and comorbidities
ariable
Mean  SD
or No. (%)
otal patients 1029
ge, year 71.6  11.2
ale 595 (57.8)
iabetes mellitus 579 (56.3)
ypertension 879 (85.4)
yperlipidemia 516 (50.1)
oronary artery disease 541 (52.6)
istory of myocardial infarction 226 (22.0)
ABG 234 (22.7)
hronic renal insufficiency 272 (26.4)
nd-stage renal disease 87 (8.5)
mokers (current and former) 563 (54.7)
ndications
Claudication 453 (44.0)
Rest pain 141 (13.7)
Tissue loss 435 (42.3)
ABG, Coronary artery bypass grafting; SD, standard deviation.
able II. Lesion location and characteristics
ariable
No. (%) or
Mean  SD
tenosis 1334 (62.4)
hronic total occlusion 615 (28.8)
n-stent restenosis 188 (8.8)
ean length, mm 100.8  9.4
ocation
Femoral 660 (30.9)
Popliteal 266 (12.4)
Tibial 513 (24.0)
Iliac 250 (11.7)
Bypass graft 59 (2.7)
Multilevel 389 (18.3)
ean runoff
Preop 1.5  .9
Postop 1.7  .8
ASC classification
A 297 (13.9)
B 632 (29.5)
C 592 (27.7)
D 616 (28.8)
D, Standard deviation; TASC, Transatlantic Inter-Society Consensus.laudication in 453 (44.0%), rest pain in 141 (13.7%), and
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Volume 53, Number 2 Shrikhande et al 349tissue loss in 435 (42.3%). Lesion characteristics and loca-
tions are reported in Table II. The mean lesion length was
100.8  9.4 mm. Mean preoperative runoff status was
1.5  0.9, and mean postoperative runoff was 1.7  0.8.
Overall, 1334 lesions (62.4%) were stenotic, 615 (28.8%)
were chronic total occlusions, and 188 (8.8%) were in-stent
restenosis (ISR).
Embolization. Table III summarizes the overall rates
of embolization. A total of 34 embolization events oc-
curred for a rate of 1.6%. The Jetstream (4 of 18, 22%) and
DiamondBack 360 (4 of 18, 22%) had significantly higher
rates of embolization than PTA alone (5 of 570, 0.9%),
PTA and stent (5 of 740, 0.7%), SilverHawk atherectomy
(14 of 736, 1.9%), and laser atherectomy (2 of 55, 3.6%;
P  .001). The rates of embolization of SilverHawk (P 
.068) and laser atherectomy (P  .076) were not signifi-
cantly different compared with PTA alone and PTA and
stent. Table IV summarizes the embolization results based
on lesion type. There was a significantly higher rate of
embolization for ISR (6 of 188, 3.2%) and chronic total
occlusions (15 of 615, 2.4%) than with stenotic lesions (13
of 1334, 0.9%; P  .01). A significantly higher rate of
embolization was found in TASC C and D lesions (26 of
1208, 2.2%) compared with TASC A and B lesions (8 of 929,
0.9%; P  .018; Table V). There was no significant differ-
ence in the embolization rates between TASC C and D
lesions (P .849). Rates of DE were not affected by pre-
operative runoff status (P .152). Furthermore, there was
no difference in DE rates between lesions undergoing
single or multiple interventions (P  .108).
Outcomes. The 24-month primary patency, assisted
Table III. Incidence of embolization based on treatment
modality
Intervention
Lesions Distal embolization
Total no. No. (%)
PTA 570 5 (0.9)
PTA  stent 740 5 (0.7)
Silverhawk ATH 736 14 (1.9)
Pathway Jetstream 18 4 (22.0)a
CSI Diamondback 18 4 (22.0)a
Laser 55 2 (3.6)
Total 2137 34 (1.6)
ATH, Atherectomy; PTA, percutaneous transluminal angioplasty.
aDenotes P  .001.
Table IV. Incidence of embolization by lesion type
Lesion type
Lesions Distal embolization
Total no. No. (%)
Stenosis 1334 13 (0.9)
Chronic total occlusions 615 15 (2.4)a
In-stent restenosis 188 6 (3.2)a
Total 2137 34 (1.6)
aDenotes P  .05 compared with stenosis.primary patency, and secondary patency in the group where gmboli occurred was 54.0%  11.9%, 70.0%  10.3%, and
3.2%  10.3%, respectively, while it was 44.4%  1.7%,
1.5%  1.7%, and 68.2%  1.6%, respectively, in cases
here embolization did not occur (primary, P  .439;
rimary assisted, P  .844; secondary, P  .813). Limb
alvage was 72.6%  3.1% in lesions in which no DE
ccurred vs 83.3%  15.2% in lesions in which DE did
ccur (P  .699; Table VI). There were no cases of digital
mputations in the DE group. Kaplan-Meier curves for
4-month patency for DE and non-DE groups are shown
n Fig 1 and Fig 2. Cox multivariate regression model
howed that diabetes mellitus, chronic renal insufficiency,
urrent smoking, and critical limb ischemia were indepen-
ent predictors of decreased primary, primary assisted, and
econdary patency (P  .05) but DE was not (P  .05;
able VII).
ISCUSSION
There is little literature describing the phenomenon of
mbolization during percutaneous procedures of the lower
xtremity arteries.6-8 Numerous studies have confirmed the
resence of particulate matter in filters after intervention;
owever, they do not provide a measure of clinically signif-
cant embolization.12-15 Our previous work suggested a 1%
ate for significant embolization after femoral and popliteal
ntervention.6 Studies on the rate of embolization after
arotid intervention are often based on duplex detection of
articles or analysis of collected debris. Although these
tudies show that embolization does occur, they are incom-
lete in that they do not describe the natural history of
hese phenomena.More sophisticated studies in the carotid
iterature analyze brain lesions during carotid stenting and
emonstrate the efficacy of protection in preventing le-
ions.17 The role of embolic protection in percutaneous
reatment of coronary vein graft lesions is well estab-
ished.18,19 In contrast, the role of distal protection in
reatment of native coronary arteries is not clearly estab-
ished.20,21 By reviewing a large number of lower extremity
nterventions, we sought to provide a clearer understanding
f the incidence of clinically significant embolization. We
lso attempted to describe device characteristics and risk
actors and effects of these events in this vascular bed, where
ercutaneous intervention is becoming commonplace.
In this series of 2137 lesions with lower extremity
rterial interventions, we encountered 34 cases of angio-
able V. Embolization based on Transatlantic Inter-
ociety Consensus (TASC)
TASC
Lesions Distal embolization
Total no. No. (%)
/B 929 8 (0.9)
/D 1208 26 (2.2)a
otal 2137 34 (1.6)
Denotes P  .05.raphically evident embolization. We found no difference
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lization and those who did not; however, these results must
be viewed with caution because the event rate was so low.
This is similar to our previous results and confirms that
acute limb loss from embolization during percutaneous
intervention is rare.6 When reviewing the 34 cases where
embolization occurred, restoration of patency was achieved
in all but two. The usual salvage techniques were suction
and mechanical thrombectomy. Although angiographic
restoration of flow occurred, it is unclear whether the
particulate debris and its treatment may have caused some
damage to the vessel in question, leading to some long-term
Table VI. Comparison of patency and limb salvage rates
Patency
6 mon
Mean  SD
Primary patency
No DE 75.7  1.2
DE 74.1  8.4
P .884
Primary asst. patency
No DE 82.8  1.0
DE 77.8  8.0
P .631
Secondary patency
No DE 86.2  .9
DE 81.3  7.5
P .511
Limb salvage
No DE 85.8  1.9
DE 83.3  15.2
P .854
DE, Distal embolization; SD, standard deviation.
Fig 1. Kaplan-Meier curves for 24-month primary, ass
lesions in which distal embolization did not occur. The esequelae. With this in mind, the 24-month primary patency, pssisted primary patency, and secondary patency in the group
here emboli occurredwas not statistically significantly differ-
nt from the group with no DE. Limb salvage rates were also
ot different between the two groups. This suggests that
omplete resolution of macroembolization may not affect
ong-term patency and limb salvage.
It would be potentially beneficial to identify device
haracteristics and lesion types that make embolization
ore likely in order to decide who would benefit from
istal protection. We noticed higher rates of embolization
ith the rotational atherectomy Jetstream device and the
rbital atherectomy Diamondback 360 device when com-
mon 18 mon 24 mon
 SD Mean  SD Mean  SD
 1.4 49.0  1.6 44.4  1.7
 9.1 54.0  11.9 54.0  11.9
35 .376 .439
 1.3 66.2  1.5 61.5  1.7
 8.0 70.0  10.3 70.0  10.3
28 .530 .844
 1.2 72.3  1.4 68.2  1.6
 7.5 73.2  10.3 73.2  10.3
95 .660 .813
 2.5 74.5  2.9 72.6  3.1
 15.2 83.3  15.2 83.3  15.2
25 .739 .699
primary and secondary patencies, and limb salvage for
bars show standard error of survival.12
Mean
58.5
69.4
.4
73.8
77.8
.8
79.6
81.3
.9
78.2
83.3
.8istedared with PTA, PTA and stent, and the directional
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Volume 53, Number 2 Shrikhande et al 351SilverHawk atherectomy device. Some atherectomy cases also
had angioplasty and stenting; however, we were able to
confirm in all cases that the event took place immediately
after the atherectomy. Other groups have identified signif-
icant particulate embolization after atherectomy; however,
once again, the clinical effects have not been confirmed.11
Fig 2. Kaplan-Meier curves for 24-month primary, ass
lesions in which distal embolization did occur. The err
indicate the standard error 10%.
Table VII. Cox multivariate analysis of risk factors
Variable HR (95% CI) P
Primary patency
Diabetes mellitus 1.22 (1.02-1.45) .028
Chronic renal insufficiency 1.25 (1.04-1.50) .017
Current smoking 1.39 (1.09-1.77) .007
Critical limb ischemia 2.20 (1.84-2.63) .001
Embolization 0.81 (0.46-1.4) .457
Primary assisted patency
Diabetes mellitus 1.25 (1.05-1.56) .045
Chronic renal insufficiency 1.44 (1.16-1.79) .001
Current smoking 1.57 (1.18-2.09) .002
Critical limb ischemia 3.12 (2.46-3.96) .001
Embolization 1.02 (0.559-1.88) .934
Secondary patency
Diabetes mellitus 1.31 (1.02-1.68) .033
Chronic renal insufficiency 1.64 (1.29-2.08) .001
Current smoking 1.58 (1.16-2.16) .004
Critical limb ischemia 3.18 (2.42-4.18) .001
Embolization 1.20 (0.637-2.28) .565
Limb salvage
Diabetes mellitus 1.68 (0.912-3.11) .096
Chronic renal insufficiency 1.57 (0.964-2.56) .071
Current smoking 1.75 (0.884-3.44) .108
Embolization 1.48 (0.340-6.44) .602
CI, Confidence interval; HR, hazard ratio.Interestingly, the Jetstream was noted to have a distal ombolus in 1 of 15 cases in a pilot study.22 The Rotablator
Boston Scientific, Natick, Mass) device had a 10% inci-
ence of significant embolization in peripheral interven-
ions.23 From these data and our findings, as well as an
nderstanding of the devices, it appears that these systems
ay have increased risk for significant distal embolization
f particulate debris. This has led us to use these devices
ith more caution. Also, given the cost of these atherec-
omy devices, one can consider using other devices that
ave low embolic potential.
Numerous studies have performed lower extremity inter-
ention with distal protection and demonstrated that debris is
ollected.11-15 These studies have been cited as evidence to
upport the use of distal protection during lower extremity
ntervention. The critical shortcoming of these studies is that
hey are small series without controls and therefore only
emonstrate that debris is collected in filters. Some of these
tudies make claims about prevention of clinically significant
vents; however, as is clear from our study, the numbers they
nclude are too small to make such conclusions.
In the Preventing Lower Extremity Distal Emboliza-
ion Using Embolic Filter Protection (PROTECT) study,
6 lesions were treated in 40 patients, all with distal pro-
ection filters.14 The authors noted significant debris in 55%
f patients. A side branch embolization occurred in one pa-
ient (2.5%) despite filter use, and a no-flow phenomenon
ccurred in another as a result of an overfilled filter. The
otential benefit of distal protection must therefore be bal-
nced against a demonstrated real complication rate associated
ith these devices. In addition, in the absence of solid evi-
ence to support their use, onemust also consider the expense
primary and secondary patencies, and limb salvage for
rs show the standard error of survival; the broken linesisted
or baf these devices.
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lesion types that are more prone to embolization. TASC C
and D lesions had higher rates of embolization than TASC
A and B lesions (2.2% vs 0.9%, P .018). Further, total
occlusions (2.4%) or ISR (3.2%) had a higher rate of DE
than native stenotic lesions (0.9%; P.01). The higher rate of
DE in ISR could reflect the nature of the material within the
stent, which may be softer and more friable than standard
atherosclerotic plaque. Further, DE was not influenced by the
number of runoff vessels, and therefore, the decision to proceed
with aggressive endovascular intervention for lower extremity
revascularization should not be based on limited runoff.
This study has some limitations that require attention.
First, when our database was started, intraoperative evi-
dence of embolization was not a measured end point, and
therefore, analysis relied on a retrospective review of angio-
grams and operative reports.
Second, a smaller number of lesions were treated with
the newer atherectomy devices in comparison with other
groups. Also, these devices potentially have a learning
curve, which was not controlled for in this study.
In addition, the effect of subintimal vs luminal crossing on
embolization rates was not analyzed. However, preinterven-
tion and postintervention images of runoff were available for
analysis for all patients, thus allowing effective assessment of
any significant change in runoff status. Assessment of collater-
als and vessels in the foot was not routinely performed and
therefore we cannotmake a definitive statement regarding the
preservation of collaterals and distal foot vessels.
CONCLUSIONS
Despite these limitations, we show that angiographi-
cally significant embolization occurs at a low rate during
percutaneous lower extremity intervention. Although rare,
it does not affect patency rates and limb salvage if runoff can
be re-established using salvage techniques at the time of the
procedure. Embolic protection may be considered for cer-
tain atherectomy devices, TASC C and D lesions, as well as
chronic total occlusions and ISR.
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